Lineage Cell Therapeutics
LCTX
92 hedge funds and large institutions have $146M invested in Lineage Cell Therapeutics in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 14 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
157% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 14
15% more funds holding
Funds holding: 80 → 92 (+12)
1.35% more ownership
Funds ownership: 43.4% → 44.75% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $153M → $146M (-$6.96M)
13% less call options, than puts
Call options by funds: $127K | Put options by funds: $146K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.04M |
| 2 |
Morgan Stanley
New York
|
+$661K |
| 3 |
Bank of New York Mellon
New York
|
+$430K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$366K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$526K |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$164K |
| 3 |
Canada Life
Winnipeg,
Manitoba, Canada
|
-$83.9K |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$70K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$69.7K |
LCTX Hedge Fund Activity: Q4 2016 in Review
92 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2016, worth a combined $146M — down 4.5% from $153M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LCTX positions and 3 closed out — a net gain of 12 holders — while 36 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.04M. The largest seller was Manatuck Hill Partners, cutting an estimated $526K.
- 92 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2016, up from 80 in Q3 2016.
- Funds reported $146M of Lineage Cell Therapeutics stock for Q4 2016, down 4.5% quarter-over-quarter.
- 15 funds opened new Lineage Cell Therapeutics positions in Q4 2016 and 3 closed out, a net change of +12 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $1.04M added.
- The largest Lineage Cell Therapeutics seller in Q4 2016 was Manatuck Hill Partners, an estimated $526K sold.
Based on aggregated 13F filings for Q4 2016.